en · de · es · fr · pt
peptide-index.peptides6155.com › Data › Molecular Basis And Receptor Pharmacology — Common Mistakes

Molecular Basis And Receptor Pharmacology — Common Mistakes

By Editorial Desk · published 2026-01-21 · last reviewed 2026-03-08 · Data

This is a working overview of 白蛋白结合, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-03-08. Anything still debated is marked as such rather than presented as settled.

Molecular Basis and Receptor Pharmacology

An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.

Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.

Background and Dual Receptor Pharmacology

Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.

Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.

Tirzepatide at a glance

PropertyValueNotes
Molecular formulaC225H348N48O68Free base form
Molecular massApproximately 4813 DaCalculated from the sequence
Amino acid residues39GIP-derived backbone
Receptor targetsGIP and GLP-1Dual agonist
Circulating half-lifeAbout 5 daysSupports weekly administration

Background and Molecular Development

Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.

The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.

Related pages on this site

Tirzepatide 分子背景与靶点

当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体,而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录,可作为分析检测和质量研究的参照。

Tirzepatide 是一种由 39 个氨基酸组成的合成肽,分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰,使其能够同时与葡萄糖依赖性促胰岛素多肽(GIP)受体和胰高血糖素样肽-1(GLP-1)受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道,随后进入糖尿病与体重管理领域的临床研究。

在生理层面,GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素,进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路,使胰岛素分泌的葡萄糖依赖性增强,并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比,双靶点作用在血糖控制和体重变化上的效应幅度更大,但具体贡献比例仍在研究之中。

Dual Incretin Receptor Pharmacology

Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.

At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.

Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.

Molecular Background and Dual Receptor Action

Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.

Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.

Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.

Reference notes

=== How they were built and why they were effective === Studies have indicated that when terraces like the ones in the Colca Valley were being constructed, the first step was excavating into the slope, and then a subsequent infilling of the slope. A retaining wall was built to hold the fill material. This wall had many uses, including absorbing heat from the sun during the day and radiating it back out at night, often keeping crops from freezing in the chilling nighttime temperatures, and holding back the different layers of sediment. After the wall is built, the larger rocks would be placed on the bottom, then smaller rocks, then sand, then soil. Since the soil was now level, the water did not rush down the side of the mountain, which is what causes erosion. Previously, this erosion was so powerful that it had potential to wipe out major areas of the Inca road, as well as wash away all of the nutrients and fertile soil. Not only was it serving a purpose in crops it also was able to support canals due to the high altitude which would accumulate water and further transport it to other sections. Since the soil never washed away, nutrients would always be added from previously grown crops year after year. The Inca even grew specific crops together, to balance out the optimal amount of nutrients for all plants. For example, a planting method is known as "three sisters" incorporated the growth of corn, beans, and squash in the same terrace.

For example, along the Greek-Turkish border, all travellers entering and exiting the Ottoman Empire would be quarantined for 9–15 days. Armed guards often manned the stations. If plague appeared, the Ottoman army would be deployed to enforce border control and monitor disease.

nuclear localization signal (NLS) Also nuclear localization sequence. An amino acid sequence within a protein which serves as a molecular signal marking the protein for transport into the nucleus, typically consisting of one or more short motifs containing positively charged amino acid residues exposed on the mature protein's surface (especially lysines and arginines). Though all proteins are translated in the cytoplasm, many whose primary biological activities occur inside the nucleus (e.g. transcription factors) require nuclear localization signals identifiable by molecular chaperones in order to cross the nuclear envelope. Contrast nuclear export signal.

=== Manuscript locations === Before his death, Tolkien negotiated the sale of the manuscripts, drafts, proofs and other materials related to his then-published works—including The Lord of the Rings, The Hobbit and Farmer Giles of Ham—to the Department of Special Collections and University Archives at Marquette University's John P. Raynor, S.J., Library in Milwaukee, Wisconsin, United States. After his death his estate donated the papers containing Tolkien's Silmarillion mythology and his academic work to the Bodleian Library at Oxford University. The Bodleian Library held an exhibition of his work in 2018, including more than 60 items which had never been seen in public before. In 2009 a partial draft of Language and Human Nature, which Tolkien had begun co-writing with Lewis but had never completed, was discovered at the Bodleian Library.

Sources: en.wikipedia.org

Notes from published material

Tetrameric, dimeric, and, more recently, monomeric αM protease inhibitors have been identified. α2-Macroglobulin is able to inactivate an enormous variety of proteinases (including serine-, cysteine-, aspartic- and metalloproteinases). It functions as an inhibitor of fibrinolysis by inhibiting plasmin and kallikrein. It functions as an inhibitor of coagulation by inhibiting thrombin. α2-Macroglobulin has in its structure a 35 amino acid "bait" region. Proteinases binding and cleaving the bait region become bound to α2M. The proteinase–α2M complex is recognised by macrophage receptors and cleared from the system.

== Prognosis == IRIS has a reported mortality rate of 4.5%. Mortality rates vary and depend on the associated OI, degree of immunosuppression, geography, and access to treatment. IRIS affecting the central nervous system has generally been associated with the highest mortality rates (13-75%).

The use of venom across a wide variety of taxa is an example of convergent evolution. In animals, venom usage has evolved independently at least 104 times, across 8 phyla. It is difficult to conclude exactly how this trait came to be so intensely widespread and diversified. The multigene families that encode the toxins of venomous animals are actively selected, creating more diverse toxins with specific functions. Also, a number of animal species have been demonstrated to acquire venom toxins from other sources, notably from associated microbes, which may even inhabit their venom apparatuses. Venoms adapt to their environment and victims, evolving to become maximally efficient on a predator's particular prey (particularly the precise ion channels within the prey). Consequently, some venoms may become specialized to an animal's standard diet.

Sources: en.wikipedia.org

Further detail

Incestuous matings by the purple-crowned fairy wren Malurus coronatus result in severe fitness costs due to inbreeding depression (greater than 30% reduction in hatchability of eggs). Females paired with related males may undertake extra pair matings (see Promiscuity#Other animals for 90% frequency in avian species) that can reduce the negative effects of inbreeding. However, there are ecological and demographic constraints on extra pair matings. Nevertheless, 43% of broods produced by incestuously paired females contained extra pair young. Inbreeding depression occurs in the great tit (Parus major) when the offspring produced as a result of a mating between close relatives show reduced fitness. In natural populations of Parus major, inbreeding is avoided by dispersal of individuals from their birthplace, which reduces the chance of mating with a close relative. Southern pied babblers Turdoides bicolor appear to avoid inbreeding in two ways. The first is through dispersal, and the second is by avoiding familiar group members as mates. Cooperative breeding in birds typically occurs when offspring, usually males, delay dispersal from their natal group in order to remain with the family to help rear younger kin. Female offspring rarely stay at home, dispersing over distances that allow them to breed independently, or to join unrelated groups. In general, inbreeding is avoided because it leads to a reduction in progeny fitness (inbreeding depression) due largely to the homozygous expression of deleterious recessive alleles.

Draculin is a noncompetitive, tight-binding inhibitor of FXa. The inhibition upon contact with the blood of the victim is immediate. Draculin forms equimolar complexes with factor FXa. The formation of Draculin-factor Xa is a two-stage process. The first reversible stage is characterized by the following constants: k1 = 1.117*106 M-1*sec-1, k-1 = 15.388*10-1 sec-1. The second irreversible (concentration-independent) stage is characterized by the forward reaction rate constant k2 = 0.072 sec-1. The dissociation constant is determined as the ratio k-1/k1 = 13.76 nM. Because of the immediate inhibition, the reaction is not readily reversible initially, but is a reversible reaction. It does not act on thrombin, trypsin or chymotrypsin and does not express fibrinolytic activity. The protein increases the lag phase as well as the height of the peak of thrombin generation when in plasma, leading to prolonged bleeding. The biological activity of Draculin is highly dependent on glycosylation of the native protein and can be severely affected by the salivation pattern of the animals.

According to prosecutor Garzón, Agüero did so as a modus operandi while she visited the resuscitation room with the newborns in her arms. In April 2023, the prosecution added the testimony of the mother of one of the babies who survived the assault. The woman personally accused Agüero and placed her at the side of her baby when the baby decompensated. On 9 August 2023, prosecutor Garzón said that the investigation had entered "its final phase," adding that his office had received reports of two other suspicious deaths of babies. Garzón also said that before going to trial, the prosecution would add more testimonies and witness evidence. On 23 August 2023, the prosecution released the results of the investigation of Agüero's cellphone, where investigators found nine PDF files. Among the nine files, the prosecution said that information was found on how to dose potassium, information related to cardiac arrests, numerous pages of neonatal medications, CPR manuals, and an article on how medical personnel should react to families grieving a newborn. Agüero's defense argued that these files were not downloaded by Agüero herself, but instead, sent to her via WhatsApp. In September 2023, the prosecution added the analysis by a team of criminal profilers who determined that the killings were acts of serial murder and that a single perpetrator was behind them. Without mentioning Agüero, prosecutor Garzón said that the analysis will be a key to the case, because the profilers also pointed to a person with access to the babies and who did not initially raise any suspicion.

The dominions and colonies provided 57 contingents, overwhelmingly of volunteer forces as none had a substantial full-time force; those from Canada alone numbered some 7,400 Altogether, Britain and her empire deployed some half a million soldiers. After the South African War, the Conservative government embarked on a series of reorganisations that had a negative impact on all the auxiliary forces. The Militia was heavily understrength and disorganised, whilst the number of recruits for the Volunteers was falling off and it was becoming apparent that many Volunteer Corps were headed towards financial collapse unless some action was taken. The Territorial Force was created by the Secretary of State for War, Richard Burdon Haldane, following the enactment of the Territorial and Reserve Forces Act 1907 which combined and re-organised the old Volunteer Force with the Yeomanry. As part of the same process, the remaining units of militia were converted to the Special Reserve. Most Volunteer infantry units had unique identities, but lost these in the reorganisation, becoming Territorial battalions of Regular Army infantry regiments. Only one infantry unit, the London Regiment, has maintained a separate identity. The TF was formed on 1 April 1908 and contained fourteen infantry divisions, and fourteen mounted yeomanry brigades. It had an overall strength of approximately 269,000. Haldane designed it to provide a much larger second line for the six divisions of the Expeditionary Force which he was establishing as the centerpiece of the Regular Army.

Sources: en.wikipedia.org

Frequently asked questions

Which receptors does tirzepatide target?

It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.

Why is the dosing interval so long?

A fatty diacid side chain promotes binding to albumin, which delays clearance from circulation. The half-life of roughly five days makes a weekly schedule practical.

Is tirzepatide naturally occurring?

No. It is a synthetic peptide whose backbone is based on the natural incretin hormone GIP. Non-natural residues and the lipid side chain were engineered to improve stability and duration of action.

What class of therapeutic is tirzepatide?

It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.

Network